EverHint Signals – EMA, MACD, SMA Crossovers – Top 30 Buy and Top 9 Sell Signals for Oct 27, 2026
Excerpt: 39 signals (from 126 total). Technology leads (24). price range $3-$381. 1 with insider buying. 7 with insider selling.
EMA 10/30 Crossover
Detects fresh crossovers between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30), generating both buy and sell signals. Uses two EMAs instead of EMA + SMA, making it more responsive to price changes and better suited for capturing short-to-medium term momentum shifts.
Entry Criteria:
- Buy: EMA10 crosses above EMA30
- Sell: EMA10 crosses below EMA30
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 1-4 weeks | Risk level: Medium
🟢 Buy Signals (10 of 46)
Ranked by RSI (lower RSI for buy signals = more oversold)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | ABCL | AbCellera Biologics Inc. | Healthcare | $12.83 | — | — | $4.2B |
| 2 | ABSI | Absci Corporation | Healthcare | $10.57 | — | — | $1.8B |
| 3 | ALKS | Alkermes plc | Healthcare | $44.32 | — | — | $7.4B |
| 4 | AVNT | Avient Corporation | Basic Materials | $42.43 | — | — | $3.9B |
| 5 | AX | Axos Financial, Inc. | Financial Services | $92.30 | — | — | $5.2B |
| 6 | BAM | Brookfield Asset Manag... | Financial Services | $46.75 | — | — | $74.7B |
| 7 | BIO | Bio-Rad Laboratories, ... | Healthcare | $380.99 | — | — | $10.2B |
| 8 | CDNS | Cadence Design Systems... | Technology | $343.08 | — | — | $94.5B |
| 9 | ES | Eversource Energy | Utilities | $67.76 | — | — | $25.5B |
| 10 | FDX | FedEx Corporation | Industrials | $307.10 | — | — | $72.7B |
🔴 Sell Signals (5 of 26)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | AWI | Armstrong World Indust... | Industrials | $155.36 | — | — | $6.6B |
| 2 | BBD | Banco Bradesco S.A. | Financial Services | $2.91 | — | — | $32.5B |
| 3 | BTSG | BrightSpring Health Se... | Healthcare | $58.35 | — | — | $11.5B |
| 4 | CHYM | Chime Financial, Inc. ... | Financial Services | $28.55 | Sell -$351,162 | — | $10.8B |
| 5 | COCO | The Vita Coco Company,... | Consumer Defensive | $54.76 | — | — | $3.1B |
Insider selling (7d): CHYM (-$351,162)
EMA 10 + Price + MACD
Experimental strategy combining price crossing above EMA10 from below with MACD Line crossing above Signal Line from below. Both conditions must occur on the same day for a signal, providing double confirmation and higher-quality setups.
Entry Criteria:
- Buy: Price > EMA10 AND MACD line crosses above signal line
- Sell: Price < EMA10 AND MACD line crosses below signal line
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh signal: All conditions met on today's close
Holding period: 1-3 weeks | Risk level: Medium-High
🟢 Buy Signals (10 of 32)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | ADEA | Adeia Inc. | Technology | $22.70 | — | — | $2.5B |
| 2 | ALGT | Allegiant Travel Company | Industrials | $73.59 | — | — | $2.0B |
| 3 | ARCB | ArcBest Corp | Industrials | $130.34 | — | — | $2.9B |
| 4 | ARMK | Aramark | Industrials | $55.52 | — | — | $14.6B |
| 5 | ATAT | Atour Lifestyle Holdin... | Consumer Cyclical | $32.75 | — | — | $4.5B |
| 6 | AZZ | AZZ Inc. | Industrials | $137.29 | — | — | $4.1B |
| 7 | BCRX | BioCryst Pharmaceutica... | Healthcare | $8.10 | — | — | $2.1B |
| 8 | BDC | Belden Inc. | Technology | $107.48 | — | — | $4.2B |
| 9 | BWXT | BWX Technologies, Inc. | Industrials | $134.07 | — | — | $12.3B |
| 10 | CORZ | Core Scientific, Inc. | Technology | $14.27 | — | — | $4.6B |
SMA 20/50 Crossover
Detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50). Uses two SMAs, making it more stable and less prone to false signals compared to EMA-based strategies. Well-suited for identifying medium-term trend changes with higher reliability.
Entry Criteria:
- Buy: SMA20 crosses above SMA50
- Sell: SMA20 crosses below SMA50
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 2-6 weeks | Risk level: Medium
🟢 Buy Signals (10 of 18)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | AGYS | Agilysys, Inc. | Technology | $115.81 | — | — | $3.3B |
| 2 | BL | BlackLine, Inc. | Technology | $34.09 | — | — | $2.0B |
| 3 | CHRD | Chord Energy Corporation | Energy | $153.31 | — | — | $8.4B |
| 4 | DLO | Dlocal Limited | Technology | $14.05 | — | — | $4.1B |
| 5 | EQT | EQT Corporation | Energy | $56.34 | — | — | $35.2B |
| 6 | GWRE | Guidewire Software, Inc. | Technology | $169.15 | Sell -$999,000 | — | $13.9B |
| 7 | HOG | Harley-Davidson, Inc. | Consumer Cyclical | $29.44 | — | — | $3.1B |
| 8 | HPQ | HP Inc. | Technology | $33.58 | — | — | $30.3B |
| 9 | IBM | International Business... | Technology | $250.25 | — | — | $236.5B |
| 10 | KNSA | Kiniksa Pharmaceutical... | Healthcare | $89.20 | — | — | $7.0B |
🔴 Sell Signals (4 of 4)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | ADPT | Adaptive Biotechnologi... | Healthcare | $27.66 | Sell -$471,314 | — | $4.4B |
| 2 | ANET | Arista Networks, Inc. | Technology | $187.00 | Sell -$21,204 | — | $235.8B |
| 3 | BRKR | Bruker Corporation | Healthcare | $60.74 | — | — | $9.3B |
| 4 | PGEN | Precigen, Inc. | Healthcare | $6.15 | — | — | $2.2B |
Insider selling (7d): ADPT (-$471,314), ANET (-$21,204), GWRE (-$999,000)
Recent Headlines
EQT (EQT Corporation)
- EQT Corporation (EQT) Surpasses Q3 Earnings Estimates
- Range Resources Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Range Resources Corporation - RRC
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.